SIBN

SI-BONE Inc

Add to Watchlist

Advanced Chart

16.670

+0.05(0.301%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

16.860

Open

16.660

VWAP

16.70

Vol

197.39K

Mkt Cap

719.16M

Low

16.530

Amount

3.30M

EV/EBITDA(TTM)

Total Shares

41.20M

609.13M

EV/OCF(TTM)

P/S(TTM)

3.80

SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

53.71M

+13.57%

-0.145

-3.33%

54.04M

+10.29%

-0.130

+18.18%

46.67M

+15.7%

-0.165

+3.13%

Estimates Revision

The market is revising Upward the revenue expectations for SI-BONE, Inc. (SIBN) for FY2025, with the revenue forecasts being adjusted by 0.43% over the past three months. During the same period, the stock price has changed by -11.61%.

Revenue Estimates for FY2025

Revise Upward

+0.43%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-7.07%

In Past 3 Month

Stock Price

Go Down

-11.61%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast SIBN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SIBN is 23.33 USD with a low forecast of 17.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 16.670

Low

17.00

Averages

23.33

High

28.00

Current: 16.670

Low

17.00

Averages

23.33

High

28.00

Needham

David Saxon

Strong Buy

Reiterates

$19

2025-01-13

Reason

Needham

David Saxon

Price Target

$19

2025-01-13

Reiterates

Strong Buy

Reason

Needham

David Saxon

Strong Buy

Reiterates

$19

2024-11-20

Reason

Needham

David Saxon

Price Target

$19

2024-11-20

Reiterates

Strong Buy

Reason

Needham

David Saxon

Strong Buy

Reiterates

$19

2024-11-13

Reason

Needham

David Saxon

Price Target

$19

2024-11-13

Reiterates

Strong Buy

Reason

Truist Securities

Samuel Brodovsky

Strong Buy

Maintains

$16 → $18

2024-11-13

Reason

Truist Securities

Samuel Brodovsky

Price Target

$16 → $18

2024-11-13

Maintains

Strong Buy

Reason

Truist Securities

Samuel Brodovsky

Strong Buy

Maintains

$18 → $16

2024-10-14

Reason

Truist Securities

Samuel Brodovsky

Price Target

$18 → $16

2024-10-14

Maintains

Strong Buy

Reason

Truist lowered the firm's price target on SI-Bone to $16 from $18 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results for the MedTech sector. While the firm believes that any hurricane related headwind call-outs for Q4 will generally get "a pass" from investors, it could cause companies with elective or deferrable procedure areas to see more muted guide increases, the analyst tells investors in a research note. For the stock, Truist contends that it sees a modest Q3 revenue beat while noting Si-Bone's operational catalysts that include "TORQ TNT for pelvic fracture launch" and achieving positive EBITDA in Q4 that generally create a good setup heading into the print.

See All Ratings

Valuation Metrics

The current forward P/E ratio for SI-BONE Inc (SIBN.O) is -29.68, compared to its 5-year average forward P/E of -17.38. For a more detailed relative valuation and DCF analysis to assess SI-BONE Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-17.38

Current PE

-29.68

Overvalued PE

-11.99

Undervalued PE

-22.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

46.10

Current EV/EBITDA

88.85

Overvalued EV/EBITDA

387.36

Undervalued EV/EBITDA

-295.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.75

Current PS

3.41

Overvalued PS

8.19

Undervalued PS

3.30